公开(公告)号：WO2021127495A1

公开(公告)日：2021-06-24

申请号：PCT/US2020/066096

申请日：2020-12-18

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： WU, Jiaxi ,  ZHANG, Tong ,  MOLINA-PORTELA, Maria del Pilar ,  SMITH, Eric ,  LIN, Chia-Yang ,  MEAGHER, Thomas

IPC: C07K16/46 ,  C07K14/54 ,  A61P35/00 ,  A61P37/06 ,  A61K2039/505 ,  A61K2039/5156 ,  A61K2039/585 ,  A61K35/17 ,  A61K38/00 ,  A61K39/0011 ,  A61K39/12 ,  A61K39/39 ,  A61K47/6849 ,  A61P31/14 ,  A61P31/20 ,  C07K14/5443 ,  C07K14/55 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70539 ,  C07K14/70578 ,  C07K14/7155 ,  C07K16/084 ,  C07K16/2818 ,  C07K2317/34 ,  C07K2317/622 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/30 ,  C07K2319/33 ,  C12N2710/16134 ,  C12N2710/20034 ,  C12N2740/13034

Abstract: The present disclosure relates to IL2 agonists with improved therapeutic profiles.

公开(公告)号：WO2022235628A1

公开(公告)日：2022-11-10

申请号：PCT/US2022/027413

申请日：2022-05-03

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： SHEN, Yang ,  LEE, Ann-Hwee ,  LIN, Chia-Yang ,  AVVARU, Naga Suhasini ,  DAVIS, Samuel

IPC: C07K16/28 ,  C07K16/2863 ,  C07K2317/31 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/71 ,  C07K2317/75 ,  C07K2317/92

Abstract: Multispecific binding molecules (MBMs) comprising at least three antigen binding sites that bind to FGR1c, the GH1 domain of Klotho beta ("KLB"), and the GH2 domain of KLB, pharmaceutical compositions containing the MBMs, methods of using the MBMs and pharmaceutical compositions for treating metabolic diseases, nucleic acids encoding the MBMs, cells engineered to express the MBMs, and methods of producing MBMs.

公开(公告)号：WO2023086812A1

公开(公告)日：2023-05-19

申请号：PCT/US2022/079530

申请日：2022-11-09

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： SHEN, Yang ,  WANG, Bei ,  AVVARU, Naga Suhasini ,  LIN, Chia-Yang ,  MURPHY, Andrew ,  HERMANN, Aynur ,  KIM, Jee H.

IPC: C07K16/28 ,  C07K14/705

Abstract: The present disclosure relates to molecules capable of binding to both CD20 and PD1, as well as pharmaceutical compositions comprising such molecules and methods of use thereof.

公开(公告)号：WO2023004282A2

公开(公告)日：2023-01-26

申请号：PCT/US2022/073832

申请日：2022-07-18

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： CHANG, Aaron ,  WU, Jiaxi ,  ZHANG, Tong ,  BLOCH, Nicolin ,  ULLMAN, Erica ,  SMITH, Eric ,  LIN, Chia-Yang ,  DAVIS, Samuel

Abstract: The present disclosure relates to IL12 receptor agonists with improved therapeutic profiles.

公开(公告)号：WO2021127487A2

公开(公告)日：2021-06-24

申请号：PCT/US2020/066086

申请日：2020-12-18

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： WU, Jiaxi ,  ZHANG, Tong ,  MOLINA-PORTELA, Maria del Pilar ,  SMITH, Eric ,  LIN, Chia-Yang ,  MEAGHER, Thomas

IPC: C07K16/46 ,  C07K14/54 ,  A61P35/00 ,  A61P37/06 ,  A61K39/00 ,  A61K38/20 ,  A61K39/12 ,  A61K39/39 ,  A61P31/20 ,  C07K14/725 ,  C07K14/705 ,  C07K14/74 ,  C07K16/08 ,  C07K16/28 ,  A61P31/14 ,  A61K2039/505 ,  A61K2039/5156 ,  A61K2039/585 ,  A61K35/17 ,  A61K38/00 ,  A61K39/0011 ,  A61K47/6849 ,  C07K14/5443 ,  C07K14/55 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70539 ,  C07K14/70578 ,  C07K14/7155 ,  C07K16/084 ,  C07K16/2818 ,  C07K2317/34 ,  C07K2317/622 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/30 ,  C07K2319/33 ,  C12N2710/16134 ,  C12N2710/20034 ,  C12N2740/13034

Abstract: The present disclosure relates to IL2 agonists with improved therapeutic profiles.

公开(公告)号：WO2020167919A1

公开(公告)日：2020-08-20

申请号：PCT/US2020/017889

申请日：2020-02-12

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： KYRATSOUS, Christos ,  LIN, Chia-Yang ,  MURPHY, Andrew J. ,  PRASAD, Brinda ,  STAHL, Neil

IPC: A61K39/00 ,  A61P31/04 ,  C07K16/08 ,  C07K16/10 ,  C07K16/12 ,  C07K16/18 ,  C07K16/28

Abstract: According to certain embodiments, the present disclosure provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds a target antigen and a second antigen binding domain that binds a complement component. In certain embodiments, the bispecific antigen-binding molecules of the present disclosure are capable of binding to the target antigen with an EC 50 of about 10 nM or less, and/or are capable of promoting complement deposition on the target antigen with an EC 50 of about 10 nM. In certain embodiments, the bispecific antigen-binding molecules of the disclosure are useful for treating diseases in which inhibition or reduction of the growth of an infectious agent or cancer cell is desired and/or therapeutically beneficial.

公开(公告)号：WO2022266598A1

公开(公告)日：2022-12-22

申请号：PCT/US2022/072895

申请日：2022-06-13

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： WU, Jiaxi ,  BLOCH, Nicolin ,  ZHANG, Tong ,  LIN, Chia-Yang ,  DAVIS, Samuel ,  SMITH, Eric ,  ULLMAN, Erica

IPC: A61P35/00 ,  C07K16/28 ,  C07K14/55 ,  A61K2039/505 ,  C07K14/7155 ,  C07K16/2818 ,  C07K2317/21 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/00 ,  C07K2319/33

Abstract: The present disclosure relates to a fusion protein comprising an antigen-binding moiety that binds specifically to human PD-1 and an IL2 moiety, and methods of use thereof.

公开(公告)号：WO2021091953A1

公开(公告)日：2021-05-14

申请号：PCT/US2020/058798

申请日：2020-11-04

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： SHEN, Yang ,  LEE, Ann-Hwee ,  YANG, Yan ,  LIN, Chia-Yang

IPC: A61K47/68 ,  A61P3/00 ,  A61P3/06 ,  A61P3/08 ,  A61P35/00 ,  C07K16/28 ,  C07K16/40 ,  C07K16/46 ,  A61K39/00

Abstract: Multispecific binding molecules (MBMs) comprising an N-terminal scFv, a first Fab and a second Fab, MBM conjugates comprising the MBMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the MBMs and MBM conjugates, methods of using the MBMs, MBM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the MBMs, cells engineered to express the MBMs, and methods of producing MBMs.

公开(公告)号：WO2020198009A1

公开(公告)日：2020-10-01

申请号：PCT/US2020/023857

申请日：2020-03-20

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： SKOKOS, Dimitris ,  MURPHY, Andrew, J. ,  YANCOPOULOS, George, D. ,  HABER, Lauric ,  LIN, Chia-Yang

IPC: C07K16/28 ,  C07K16/30 ,  A61P35/00 ,  C07K16/40

Abstract: The present invention provides multispecific antibodies that bind to EGFR and CD28 (EGFRxCD28) as well as anti-EGFR antibodies. Such antibodies may be combined with a further therapeutic agent such as an anti-PD1 antibody. Methods for treating cancers (e.g., EGFR-expressing cancer) by administering the antibodies (e.g., and combinations thereof with anti-PD1 ) are also provided. The EGFRxCD28 antibodies of the present invention embody a tumor-targeted immunotherapeutic modality combined with PD-1 inhibition. These bispecific antibodies bind a tumor-specific antigen (TSA) (EGFR) with one arm and the co-stimulatory receptor, CD28, on T -cells with the other arm. Combination therapy with PD-1 inhibitors specifically potentiated intra-tu moral T cell activation, promoting an effector memory-like T cell phenotype without systemic cytokine secretion in a variety of syngeneic and human tumor xenograft models. Combining this class of CD28-co-stimulatory bispecific antibodies with the clinically validated anti-PD-1 treatment provides a well-tolerated antibody therapy with markedly enhanced anti-tumor efficacy.